Kytopen Corp. and Bio-Techne Corporation Collaborate on an Integrated Cellular Engineering Workflow to Expedite Cell Therapy Manufacturing

Published: 2025-05-08 09:30:00 ET TECH

Published on 05/08/2025 at 09:30, updated on 05/08/2025 at 10:35

Kytopen Corp. and Bio-Techne Corporation announced a partnership aimed at streamlining gene delivery solutions for the development and manufacture of advanced cell therapies. The collaboration will focus on the synergies developers can achieve by utilizing the TcBuster GMP non-viral genome engineering system and the Flowfect Tx GMP cellular engineering platform.

Together, these technologies offer a clear path to shortened workflows for generating more efficient genome engineering of immune cell therapies, expediting their advancement to clinical stages and subsequent manufacturing. Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods. The hyperactive TcBuster transposase enables delivery of multiple genes simultaneously while maintaining high editing efficiency and a de-risked insertional profile.

Flowfect technology is a highly tunable system. It is unique in that it combines mechanical, electrical, and chemical forces, and allows the adjustment of multiple parameters to maximize transfection efficiency, cell health, and cell yield, while continuous flow enables the processing of hundreds of billions of healthy, high-quality engineered cells in just minutes. Together these technologies provide a streamlined gene delivery process that can achieve therapeutic doses quicker.

Data generated through the collaboration will be presented at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting, May 7-10, 2025, in New Orleans, USA. The data will also be featured in Kytopen's Global Showcase Oral Presentation on May 8, 2025, at 6:00pm. For more information at ISCT, the Kytopen and Bio-techne teams will be available to answer any questions at booths 347 and booth 932, respectively.